Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ:SYRS) announced new data from the Phase 1 clinical trial of SY-5609, a potent oral CDK7 inhibitor, at the ESMO Congress 2021. The presentation includes safety and preliminary efficacy results in various cancer types. Additionally, Syros will present preclinical data on SY-5609's antitumor activity in ovarian cancer models and its effects in KRAS-mutant cancers. A conference call is scheduled for September 20, 2021, to discuss these findings, with the oral presentation's abstract embargo lifting on September 17.
Syros Pharmaceuticals (NASDAQ:SYRS) announced the appointment of Dr. Deborah Dunsire to its Board of Directors, bringing over 30 years of life sciences experience. Dr. Dunsire's leadership and expertise in oncology R&D are expected to enhance Syros' growth as it advances its hematology and CDK7 programs. She previously served as CEO of multiple biopharmaceutical companies, including H. Lundbeck A/S and Millennium Pharmaceuticals. Syros aims to develop breakthrough therapies and has a robust clinical pipeline with candidates targeting diseases like acute myeloid leukemia and solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) has initiated the dosing of the first patient in the SELECT-AML-1 clinical trial for tamibarotene, a selective RARα agonist, in combination with venetoclax and azacitidine to treat RARA-positive newly diagnosed unfit acute myeloid leukemia (AML) patients. The randomized Phase 2 trial aims to address the need for effective therapies in this patient population, which often does not respond to standard treatments. Promising prior results showed a 67% overall response rate in similar trials, emphasizing the potential of tamibarotene as a valuable treatment option.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will present at two investor conferences in September 2021, enhancing visibility for the company’s innovative gene-control medicines. The presentations are scheduled for the H.C. Wainwright Annual Global Investment Conference on September 13 at 7:00 a.m. ET, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 2:05 p.m. ET. Webcasts will be available on the Syros website, with archived recordings accessible for 30 days.
Syros Pharmaceuticals (SYRS) reported its Q2 2021 financial results, showing revenues of $5.2 million, up from $3.2 million in Q2 2020. The net loss was $22.5 million, or $0.36 per share. Cash, cash equivalents, and marketable securities totaled $195.3 million as of June 30, 2021. The company is advancing its portfolio in targeted hematology and selective CDK inhibition, with significant milestones including collaborations with Roche for SY-5609, a selective CDK7 inhibitor. Upcoming trials are set to begin in the second half of 2021, indicating a strong focus on addressing unmet medical needs.
Syros Pharmaceuticals (NASDAQ:SYRS) has established a clinical supply agreement with Roche to provide SY-5609, an oral CDK7 inhibitor, for a combination therapy study in Roche's Phase 1/1b INTRINSIC trial. This trial targets colorectal cancer patients and explores SY-5609's efficacy in conjunction with atezolizumab. Roche will sponsor the study and cover associated costs, while Syros retains rights to SY-5609 and will have access to study data. Previous preclinical studies suggest that SY-5609 may significantly enhance the effectiveness of immunotherapy in BRAF-mutant colorectal cancer.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on August 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. Interested parties can join the call by dialing 866-595-4538 domestically or 636-812-6496 internationally, using conference ID 4156527. The call can also be accessed via the Syros website, with a replay available for 30 days post-event. Syros is focused on developing innovative gene expression control therapies for cancer and other serious diseases.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2021 Life Sciences Conference on June 16 at 1:00 p.m. ET. A live webcast will be available on the Syros website, with an archived replay accessible for 30 days post-event. Syros focuses on innovative gene expression control with a robust clinical pipeline, including SY-1425 for myelodysplastic syndrome, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announced a three-part KOL webcast series focusing on its investigational targeted therapies in hematology. The series will cover SY-1425 for myelodysplastic syndrome and acute myeloid leukemia, along with SY-2101 for acute promyelocytic leukemia. Presentations will feature Syros leaders and guest KOLs, highlighting recent advancements and unmet needs in these diseases. Webcasts are scheduled for May 26, June 22, and July 20, 2021, each starting at 8:30 AM ET. Archived replays will be available post-event.
Syros Pharmaceuticals (NASDAQ:SYRS) reported Q1 2021 financial results, showing revenues of $4.8 million, up from $2.4 million in Q1 2020. The company is progressing in hematology with a Phase 3 trial of SY-1425 for RARA-positive higher-risk MDS, and planning to initiate further trials for SY-1425 and SY-2101 in H2 2021. R&D expenses increased to $20.0 million due to clinical advancements, while G&A expenses rose to $5.7 million. Net loss decreased to $14.2 million, or $0.23 per share. Cash reserves stood at $222.1 million, expected to fund operations through 2023.
FAQ
What is the current stock price of Syros Pharmaceuticals (SYRS)?
What is the market cap of Syros Pharmaceuticals (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
